Background-In statin trials, each 20 mg/dL reduction in cholesterol results in a 10 -15% reduction of annual incidence rates for vascular events. However, interindividual variation in low-density lipoprotein cholesterol (LDL-C) response to statins is wide and may partially be determined on a genetic basis. Methods and Results-A genome-wide association study of LDL-C response was performed among a total of 6989 men and women of European ancestry who were randomly allocated to either rosuvastatin 20 mg daily or placebo. Single nucleotide polymorphisms (SNPs) for genome-wide association (PϽ5ϫ10 Ϫ8 ) with LDL-C reduction on rosuvastatin were identified at ABCG2, LPA, and APOE, and a further association at PCSK9 was genome-wide significant for baseline LDL-C and locus-wide significant for LDL-C reduction. Median LDL-C reductions on rosuvastatin were 40, 48, 51, 55, 60, and 64 mg/dL, respectively, among those inheriting increasing numbers of LDL-lowering alleles for SNPs at these 4 loci (P trendϭ6.2ϫ10 Ϫ20 ), such that each allele approximately doubled the odds of percent LDL-C reduction greater than the trial median (odds ratio, 1.9; 95% confidence interval, 1.8 -2.1; Pϭ5.0ϫ10 Ϫ41 ). An intriguing additional association with sub-genome-wide significance (PϽ1ϫ10 -6 ) was identified for statin related LDL-C reduction at IDOL, which mediates posttranscriptional regulation of the LDL receptor in response to intracellular cholesterol levels. In candidate analysis, SNPs in SLCO1B1 and LDLR were confirmed as associated with LDL-C lowering, and a significant interaction was observed between SNPs in PCSK9 and LDLR. Conclusions-Inherited polymorphisms that predominantly relate to statin pharmacokinetics and endocytosis of LDL particles by the LDL receptor are common in the general population and influence individual patient response to statin therapy. (Circ Cardiovasc Genet. 2012;5:257-264.)
Clinical Perspective on p 264
To date, other than replicated associations at the APOE locus, 2-5 the extent of potential genetic determinants of LDL response to statin therapy has been difficult to quantify because available studies have either combined data from different statin agents at variable doses or have been restricted to candidate gene approaches. 6, 7 To overcome these limitations, we conducted a comprehensive genome-wide association study of LDL-C response to a fixed statin regimen among a population of 6989 men and women initially free of lipid-lowering therapy who were randomly allocated to rosuvastatin 20 mg daily or to placebo and then followed over a 1-year period for both absolute and fractional reduction in LDL-C.
Methods

Study Population
The study population was derived from JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), an international, randomized, placebo-controlled trial of rosuvastatin (20 mg/d) in the primary prevention of cardiovascular disease conducted among apparently healthy men and women with LDL-C Ͻ130 mg/dL and high-sensitivity C-reactive protein Ͼ2 mg/L. 8 Per study protocol, all JUPITER participants had standard lipid measurements made in a core laboratory facility before random assignment and after 1 year of placebo or rosuvastatin treatment. As anticipated, and consistent with prior statin trials, lower on-treatment LDL-C levels within JUPITER directly associate with greater clinical benefit in terms of absolute as well as relative risk reductions. 9 Approximately 71.2% of JUPITER participants had European ancestry, among whom 71.4% provided DNA and consent for genetic analysis. There were small but significant differences (PϽ0.01) among the JUPITER participants of European ancestry according to availability of DNA and consent for genetic analysis in age (median, 66.1 [DNA available] versus 65.5 years [DNA not available]), percentage of women (31.6% versus 35.2%), body mass index (median, 28.7 versus 28.1 kg/m 2 ), and current smoking (13.0% versus 17.4%). See also online-only Data Supplement Table I .
Genotyping and Analysis
Genotyping was performed using the Omni1-Quad platform (Illumina, San Diego, CA). Briefly, raw genotype intensity data were reduced to genotype calls, using the Illumina GenomeStudio (v 1.6.2) software (Illumina). Single nucleotide polymorphism (SNP) clusters were initially defined automatically using data from the JUPITER sample. Approximately 1% of the SNPs were identified for poor clustering on the basis of the ABrMean (intensity) parameter, cluster separation measures, deviation from Hardy-Weinberg equilibrium (HWE), or call frequency and were visually inspected and annotated, removed, or clustered again with manual intervention. After these procedures, 99.71% of the loci yielded successful genotype information. Clusters of intensity in the experimental genotyping for all of the SNPs described in the report were well separated and had GenomeStudio GenTrain quality scores Ͼ0.74, the mean value for all SNPs on the Omni1-Quad chip. Among the SNPs in this report, the worst clusters were found for the ABCG2 SNP rs2199936, as reflected in a GenTrain score of 0.744. Nevertheless, this SNP was in almost perfect linkage disequilibrium (LD) (r 2 ϭ0.96), with rs1481012, the other LDL-C response SNP in the ABCG2 gene, which had an exceptional GenTrain score of 0.87, reinforcing confidence in the reported associations. Cluster plots showing the raw genotype intensity data from 1435 JUPITER samples at all SNPs described in this report are shown in the Appendix of the online-only Data Supplement. In the final data used for analysis, SNPs were retained if the updated clusters met quality standards and the genotyping was successful in Ͼ90% of the samples. All associations described in this work had call rates Ͼ96.4%, with a median of 99.98% and a maximum of 100%. All samples had successful genotyping for Ͼ98.5% of the final SNPs. Of JUPITER participants with self-reported European ancestry who provided consent for genetic analysis, Ͼ99% or 8782 had successful genotyping and verification of their ancestry with identity-by-state clustering, using multidimensional scaling procedures in PLINK 10 applied to 1067 ancestry informative SNPs selected from HapMap3.
To reduce heterogeneity as well as the potential for bias and confounding, we limited this analysis of the genetic determinants of LDL-C change during follow-up to those 6989 JUPITER consented trial participants of European ancestry who also (1) had adequate baseline and follow-up blood samples available that had successfully undergone lipid and genotype determinations and (2) were deemed to be compliant with study medications on the basis of pill counts and reported absence of nontrial statin use, ie, information that was independent of LDL-C reduction.
Initially, SNPs were not excluded from analysis on the basis of deviations from HWE to ensure that all loci potentially related to LDL-C change would be evaluated. However, at the genome-wide significance threshold, the loci identified within these initial data were the same as the loci identified among SNPs not deviating from HWE (PՆ10 Ϫ6 ). Because of the inability to distinguish ascertainment effects from genotyping failures as the cause of HWE deviation, all reported analyses are restricted to SNPs not deviating from HWE (PՆ10 Ϫ6 ), with the exception of rs7412, which distinguishes the APOE E2 from E3/E4 genotypes and was retained due to its known functional impact. In total, 1 006 348 SNPs passed quality control standards, among which 814 418 had minor allele frequency Ͼ1%. Sub-European ancestral stratification was estimated using the principal component approach in EIGENSTRAT. 11 On an a priori basis, we separately evaluated statin-and placeboallocated groups for genetic association with either the absolute change in LDL-C (computed as the difference of the 12-month and baseline values) or the fractional change in LDL-C (computed as the absolute difference divided by the baseline value). Both the absolute and fractional changes in LDL-C were skewed and included outlying values. To diminish spurious influences of these nonnormal features on linear regression, the changes in LDL-C were transformed by inverse quantile normalization. 6 Association probability values were determined from the transformed variables to ensure stability of the significance estimates, whereas the magnitudes of effects were estimated from the untransformed values and by examining median values according to genotype. Both rosuvastatin-and placebo-allocated participants contributed to analyses of genetic determinants of baseline LDL-C.
Genetic association analysis was performed in PLINK. 10 The primary regression models assumed an additive relationship between the number of copies of the minor allele of each SNP and mean lipid measures. Secondary regression models included a second term, the dominant deviance term, to allow independent estimate of the effect of each genotype class. Genome-wide significance required PϽ5ϫ10 Ϫ8 . Genome-wide significant loci were defined as the contiguous segments within 100 kB of any SNP with a genome-wide significant association. Interaction analysis was performed by modifying the additive regression models with an extra term as the product of the SNP (encoded in an additive mode) and either a second SNP (also with additive encoding) or sex encoded as 0 (male) or 1 (female). Furthermore, SNPs with low minor allele frequency (Ͻ5%) were encoded as 0 (homozygotes of the major allele) or 1 (carriers of the minor allele) in the interaction analysis. In the locus-wide analysis, probability values were corrected for multiple hypothesis testing with the Sidák procedure applied to an effective number of independent SNPs (M eff ) as described. 12 Additional analytic and graphical procedures, including the regional plots, 13 were performed in R. 14 Genetic risk scores were computed as the simple sum of inherited alleles associated with greater LDL-C reduction. Separate genetic risk scores were constructed for analysis of absolute and fractional LDL-C reduction.
Results
Because of random assignment, statin-allocated (nϭ3523) and placebo-allocated (nϭ3466) participants were virtually identical at baseline with respect to all major cardiovascular risk factors including sex (32% female), median age (66 years), median plasma levels of LDL-C (110 mg/dL), high-density lipoprotein cholesterol (49 mg/dL), and triglyceride (116 mg/dL) (onlineonly Data Supplement Table I ). Overall, statin allocation resulted in a median 54 mg/dL reduction in LDL-C, with a very broad range of individual response even among those determined to be compliant with therapy (interquartile range for LDL-C reduction, 40 -66 mg/dL). Noncompliant participants with verified European ancestry had median LDL-C reduction of 0 mg/dL (interquartile range, 16 -12 mg/dL).
Genome-Wide Effects
In the primary analysis, loci meeting genome-wide significance (PϽ5ϫ10 Ϫ8 ) for absolute or fractional change in LDL-C after random allocation to rosuvastatin 20 mg were identified at ABCG2 (rs2199936), LPA (rs10455872), and APOE (rs7412) ( Table 1 , online-only Data Supplement Table  II , and online-only Data Supplement Figure I ). By contrast, no loci were identified among those allocated to placebo. At APOE, where the primary genome-wide association was with fractional LDL-C reduction, a second SNP (rs71352238) not in LD with the first (r 2 ϭ0.02) was associated with absolute LDL-C reduction with sufficient significance to account for 
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multiple hypothesis correction for APOE locus SNPs. Similarly, a SNP (rs11591147) in PCSK9 reaching genome-wide significance with baseline LDL-C also had gene-wide significance with the fractional change in LDL-C, whereas a second SNP (rs17111584) at the same PCSK9 locus not in LD with the first (r 2 ϭ0.001) reached locus-wide significance for absolute LDL-C change. Additional loci with genomewide baseline LDL-C association in other studies, for example, APOB, 15 had nominal (PϽ0.01) rather than genome-wide significant association in JUPITER, possibly due to the enrollment criterion requiring baseline LDL-C Ͻ130 mg/dL (see Methods), and were thus not considered in the genomewide analysis of LDL-C reduction. The 4 loci in Table 1 were again identified with genome-wide significance in analysis performed with residuals of the LDL-C measures after adjustment for clinical covariates including age, sex, and others including population structure eigenvectors (onlineonly Data Supplement Table III) , which eliminated the slight inflation of the test statistic (genomic control ϭ1.1 [unadjusted LDL-C reduction] and 1.0 [residuals of LDL-C reduction]). Similarly, the same loci were identified in comparable analysis performed with plasma measures of apolipoprotein B protein rather than LDL-C (data not shown). No additional loci were identified at genome-wide significance in regression models unconstrained by the additive assumption.
At ABCG2, the locus with the most significant association with absolute LDL-C reduction, the mean per allele effect of rs2199936 was Ϫ5.2 mg/dL (Table 1) , corresponding to observed median LDL-C reductions of Ϫ53, Ϫ59, and Ϫ64 mg/dL for individuals with 0, 1, or 2 copies of the minor allele, respectively (Figure 1) . At LPA, the mean per-allele change in LDL-C on rosuvastatin for rs10455872 was 6.2 mg/dL (Table 1) , corresponding to observed median LDL-C reductions of Ϫ55, Ϫ48, and Ϫ46 mg/dL, with increasing minor allele copies (Figure 1, left panels) . Smaller effects were observed for the lead SNP with absolute LDL-C reduction at PCSK9 (rs17111584) and APOE (rs71352238) ( Table 1) , the latter association appearing to have nonadditive character. A similar concordance of the regression estimates and the median fractional reduction in LDL-C was also observed ( Table 1 and Figure 1, right panels) .
Genome-wide associations with either the absolute or fractional change in LDL-C spanned about 113 kb at ABCG2 but were more restricted at LPA and APOE (Figure 2 ). Conditional analysis suggested that the strong signals at ABCG2 and LPA could be largely explained by the lead SNPs; after adjustment for the lead SNPs, rs2199936 at ABCG2 or rs10455872 at LPA, no other locus SNPs remained with genome-wide significance for either absolute or frac- tional LDL-C reduction (online-only Data Supplement Figure  II) . Similarly, at APOE, adjustment for rs7412 eliminated genome-wide signal at this locus for the fractional change in LDL-C (online-only Data Supplement Figure II) , and adjustment for the weaker associations at PCSK9 (rs17111584) and APOE (rs34095326) with absolute change in LDL-C did not reveal any conditional associations reaching genome-wide significance (data not shown).
A genetic risk score was constructed to evaluate the magnitude of the absolute reduction in LDL-C, based on alleles for lead SNPs at the 4 primary loci ( Table 1) . With regard to absolute change, median LDL-C reductions on rosuvastatin were 40, 48, 51, 55, 60, and 64 mg/dL, respectively, among individuals with between Յ3 and 8 copies of alleles that increase absolute LDL-C reduction with statin allocation at the 4 loci (SNPs from Table 1, left; risk score, Pϭ6.2ϫ10 Ϫ20 ). For this genetic risk score, each additional allele was associated with a 50% increase in the odds of having an absolute reduction in LDL-C more than 54 mg/dL, the overall median reduction for the trial (odds ratio, 1.5; 95% confidence interval, 1.4 -1.7; Pϭ3.2ϫ10 Ϫ20 ; Figure 3) .
Similarly, with regard to fractional change, median reductions on rosuvastatin were 44%, 50%, 55%, 58%, and 64%, respectively, among individuals with between Ͻ1 and 6 copies of alleles that increase fractional measures of LDL reduction with statin allocation at the 4 loci (SNPs from Table 1, center; risk score, Pϭ1.7ϫ10 Ϫ25 ). One trial participant carried 6 of the 8 possible LDL-lowering alleles and had a 76% reduction in LDL-C with rosuvastatin ( Figure 3 ). In this analysis done on a percent reduction basis, each additional allele was associated with an approximate doubling in the odds of having a fractional reduction in LDL-C more than the overall 50% change for the trial (odds ratio, 1.9; 95% confidence interval, 1.8 -2.1; Pϭ5.0ϫ10 Ϫ41 ; Figure 4 ).
Additional Effects and Biologically Selected Candidate SNPs
After excluding all SNPs within 1 Mb of the lead SNPs at the 4 genome-wide significant loci, there remained an excess of SNPs with smaller association probability values than expected under the null for the change in LDL-C on rosuvastatin (online-only Data Supplement Figure III) . At a suggestive significance threshold of PϽ10 Ϫ6 , 4 additional candidate loci were identified for LDL-C reduction on rosuvastatin ( Table 2 ). The finding at IDOL is supported by previous reports of association at this locus with plasma levels of LDL-C in untreated individuals, 16 and IDOL has recently been shown to encode an inducible regulator of the LDL receptor involved in LDL-C particle endocytosis. 17 We additionally evaluated a series of SNPs and genes that have been suggested in previous biochemical and genetic studies to be candidates for modulating response to statin therapy. For example, aside from variation at APOE, candidate SNPs in lipid metabolism pathways have been reported in HMGCR, encoding the target of statin therapy, and LDLR, encoding the LDL receptor. 2,7,18 -20 In our study, no SNP at the HMGCR locus was significantly associated with rosuvastatin associated LDL-C reduction ( Table 3 ). In contrast, rs6511720, a candidate SNP in LDLR, was significant for percent reduction in LDL-C (Ϫ2.6% per allele; Pϭ0.005). Similarly, on a locus-wide basis, the most significant SNP at LDLR for absolute LDL-C reduction (rs11672123, 4.4 mg/ dL, Pϭ7ϫ10 Ϫ4 ) was significant after correction for all locus SNPs considered (P corrected ϭ0.02, Table 3 ). Candidate genes for LDL-C change also arise in the context of pharmacody- Table 1 , left, for SNPs). Table 1 , right, for SNPs).
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namic and pharmacokinetic aspects of rosuvastatin therapy, among which significant associations were identified at SLCO1B1 (Table 3) , encoding a drug transporter previously reported for association with statin toxicity 21 in addition to associations at ABCG2 that were confirmed here at a genomewide standard ( Table 1 ). The SLCO1B1 associations included SNPs selected both from previous reports (rs4149056, rs4363657) and on the basis of locus-wide significance (rs12317268). We could not confirm other candidate associations for rosuvastatin (CYP3A5, CYP2C9) or for other statins (GRIK4, 7 CLMN, 6 ) (online-only Data Supplement Table IV ). Finally, we addressed whether genetic interactions were contributing to the variance in LDL-C reduction on rosuvastatin. In standard linear regression analysis, none of the lead SNPs (Table 1 ) displayed significant interaction with each other or with any other SNPs in the entire genome-wide panel for either absolute or fractional LDL-C reduction with rosuvastatin allocation, nor did any SNP in the study meet genome-wide criteria (PϽ5ϫ10 Ϫ8 ) for a sex interaction, including the lead SNPs and SNPs on the X chromosome. However, in exhaustive pairwise analysis among the lead SNPs at the genome-wide significant loci (Table 1 ) and the significant candidate associations (Table 3) , we observed an interaction involving PCSK9 (rs11591147) and LDLR (rs11672123) such that carriers of the minor allele of both SNPs had substantially greater LDL-C reduction than would be expected from the modest effects at either SNP alone (online-only Data Supplement Table V) . This interaction was significant at nominal standards (P interaction ϭ0.001) but not at standards accounting for correction for the full multiplicity of interaction testing.
Discussion
In this genome-wide evaluation conducted among 6989 men and women of European ancestry participating in the JUPITER trial, we identified 4 loci-ABCG2, LPA, APOE, and PSCK9-that were associated with differential effects on LDL-C reduction in patients who had been randomly allocated to rosuvastatin 20 mg daily compared with placebo. The genome-wide significant SNPs at ABCG2 and LPA, the loci with the most significant associations for absolute LDL-C, were associated with approximately 5-6 mg/dL per allele differences in LDL-C reduction compared with the median 54 mg/dL reduction for rosuvastatin allocation overall. Using genetic risk scores based on allele counts for the LDL-C-lowering SNPs at the 4 primary loci, we were able to identify patient subgroups on a genetic basis that had differences in median LDL-C reduction with statin therapy as large as 22 mg/dL (Figure 3 ). Because LDL-C reduction with statin therapy is directly related to the magnitude of cardiovascular benefit associated with these agents, 1 these data are consistent with the hypothesis that genetic variation accounts, in part, for differences in risk among individual patients allocated to statin therapy.
Although a genetic data set of adequate size, homogeneity, and uniform rosuvastatin administration for replication does not exist, we believe that our findings are robust on the basis of several key observations. First, the loci identified by the genome-wide thresholds of significance have all been related to statin response or LDL-C metabolism. Genetic variants, including the SNPs at PCSK9, ABCG2, and APOE, have been shown to affect statin if not rosuvastatin response. 7, 22 The association of SNP rs10455872 at the LPA locus with LDL-C lowering is probably related to a contribution of the cholesterol in lipoprotein (Lp)(a) particles to LDL-C measurements, 23 even though this same SNP was not strongly associated with baseline LDL-C in JUPITER ( Figure 2 ). In separate data available to us, 24 SNP effects on plasma Lp(a) particle concentration at the LPA locus are highly correlated with weaker effects on plasma LDL-C (Spearman ϭ0.9) that may be not be manifest in JUPITER as a result of the LDL-C Ͻ130 mg/dL enrollment criterion. In particular, rs10455872 is associated with both Lp(a) and LDL-C in those other data (data not shown). The genome-wide association at LPA with LDL-C reduction may thus reflect an effect on the cholesterol content of Lp(a) particles in response to statin. Second, because of the strong prior evidence for the primary loci and SNPs, the estimates of the genetic effects are not likely to be biased by the "winner's curse" phenomenon. In the genetic risk score analysis, potential bias is further minimized or essentially eliminated by the use of a simple summation of LDL-Clowering alleles rather than a weighted summation based on effect estimates. Third, because noncompliance could not be fully excluded, the effects may be underestimated to some extent. Fourth, because the JUPITER trial only enrolled those with untreated LDL-C levels below 130 mg/dL, our findings cannot be attributed solely to genetic variants associated with very high baseline LDL-C levels that might result in greater absolute levels of LDL-C reduction during follow-up. Finally, the absence of any genome-wide significant genetic effect in the randomly allocated placebo sample, where there was also a lack of nominally significant associations at the primary SNPs, including rs10455872 in LPA, provides evidence that the differential genetic effects are due solely to statin allocation and not to any other systemic cause of LDL-C change that might have occurred during follow-up.
Broadly defined, processes related to statin pharmacokinetics constitute 1 class of biological function suggested by the associations reported here. The most significant finding for absolute LDL-C reduction, rs2199936, maps to an intron of ABCG2 (Table 1) , encoding an ATP binding cassette family member first identified for multidrug resistance 25 and later shown to be associated with hepatic drug efflux, 26 including efflux of rosuvastatin, 27 as well as renal transport. 28 These previous studies focus on a nonsynonymous SNP, rs2231142, which was not genotyped on the current platform but is in LD with rs2199936 in the HapMap (CEU, r 2 ϭ0.81). The candidate analysis (Table 3) confirmed the relevance to statin therapy of SLCO1B1, encoding an organic ion transporter that was associated previously with myopathy among those treated with high-dose simvastatin. 21 LDL particle transport proximal to endocytosis by the LDL receptor represents a second biological process highlighted by this genetic analysis. Thus, the ApoE protein (APOE, Table 1 ) is a key component of chylomicrons, very lowdensity lipoprotein cholesterol, and intermediate-density lipoprotein cholesterol particles, all of which are ultimately taken up by the liver through endocytosis mediated by the LDL receptor (LDLR, Table 3 ), whereas proteins encoded by PCSK9 (Table 1 ) and IDOL (MYLIP) ( Table 2 ) are believed to regulate cell surface LDL receptor levels through degradation pathways. 17, 29 The association at IDOL represents an intriguing novel finding for genetic influence on statin response and is also consistent with prior analysis of this locus as a determinant of baseline LDL-C. These studies show how the cholesterolresponsive activity of the LXR pathway modulates expression of IDOL, a ubiquitin ligase, which subsequently controls LDL receptor family receptor protein levels by ubiquitinmediated degradation. This regulatory pathway, and specifically the Idol protein, may represent a target for future drug development. 30 In this context, it should be noted that EPB41L2, identified as the most significant sub-genomewide association (PϽ10 Ϫ6 , Table 2 ), shares with IDOL a Band 4.1 homology domain typically associated with plasma membrane localization.
Despite the large size of JUPITER, far larger data sets will be needed to address whether the appreciable genetic effects on LDL-C lowering found in the present study in turn affect clinical events. At the same time, the interindividual variation in LDL-C lowering that is not explained by the current findings may be divided between effects related to clinical characteristics, including environmental exposures, and genetic effects of additional, possibly rare variants as well as genetic interactions. In either case, the biochemical pathways identified in the present study provide a framework for optimizing statin therapy on an individual basis and provide insights for the development of additional lipid-lowering agents that might complement statin effects.
